TY - JOUR T1 - Clinical features of suspected pediatric patients with 2019 novel coronavirus infection and the role of procalcitonin in early differential diagnosis JF - medRxiv DO - 10.1101/2020.04.07.20057315 SP - 2020.04.07.20057315 AU - Denggao Peng AU - Jing Zhang AU - Yingqi Xu AU - Zhichao Liu AU - Pengyao Wu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/08/2020.04.07.20057315.abstract N2 - A retrospective analysis was performed.39 (50.6%) of 77 suspected cases were comfirmed, 4 (5.2%) of them had viral coinfection. Compared with non-2019-nCoV group(n=33),2019-nCoV confirmed group (n=39) had fewer fever and symptoms of acute respiratory infection (ARI), more asymptomatic and more family cluster infections. While computed tomography (CT) had more positive findings of viral pneumonia. Age and gender were insignificant. PCT (0.05[0.029-0.076] vs 0.103[0.053-0.21];P<.001) of 2019-nCoV alone group (n=35) was significantly reduced. While compared with coinfection group (n=4), PCT (0.05[0.029–0.076] vs 0.144[0.109–2.26];P=.003) was also statistically reduced. The area under curve (AUC) of receiver operating characteristic (ROC) of overall model is 0.817 ([95%CI] [0.719-0.916];P<.001). The AUC of PCT is 0.792 ([0.688-0.896];P<.001). The cut-off value is 0.1 ng/mL. Asymptoms or mild symptoms, positive CT findings and family cluster infection are the main clinical features of pediatric 2019-nCoV infection. With moderate efficacy, PCT can provide an important basis for differentiating 2019-nCoV alone and other viral infection or viral coinfection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDid not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in this paper is true, reliable and available. Abbreviations2019-nCoV2019 novel coronavirusAUCarea under curveARIacute respiratory infectionCIconfidence intervalCAPcommunity acquired pneumoniaCTcomputed tomographyhs-CRPhigh sensitivity C-reactive proteinHbHemoglobinINFA, Binfluenza A, BIQRinterquartile rangeLClymphocyte countL%percentage of lymphocyteMPmycoplasma pneumoniaeNPVnegative predictive valueN%percentage of neutrophilNCneutrophil countORodds ratioPPVpositive predictive valuePLTplateletPCTprocalcitoninROCreceiver operating characteristic curveRT-PCRreal-time reverse transcriptase polymerase chain reactionRSVrespiratory syncytial virusSDstandard deviationSEstandard errorWBCwhite blood cell ER -